Výsledky vyhledávání - "Erzsébet Juhász"

Introduction Pralatrexate, a folate analogue targeting dihydrofolate reductase, has antitumor activity in non–small-cell lung cancer (NSCLC). This randomized phase 2b trial was designed to further evaluate pralatrexate activity in NSCLC by estimati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8588e5c7aa858dafbe60a22f9d43cee7
https://doi.org/10.1097/jto.0b013e31824cc66c

Zobrazit plný text záznamu

Cisplatin–vinorelbine chemotherapy in non-small cell lung cancer is safe and well tolerated: results of a retrospective Hungarian clinical data analysis

Autor: Lilla Tamási, Pál Magyar, Erzsébet Juhász, Veronika Müller, Marianna Budai, Mária Szilasi

Publikováno v: Expert Opinion on Drug Safety. 8:9-14

The efficacy of cisplatin-vinorelbine chemotherapy (CT) in NSCLC is well established. In this retrospective data analysis, haematological safety and tolerability, furthermore the effects of cisplatin-vinorelbine combination on patients' quality of li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2048c2971a2b4dc240cc601b8dbec3c0
https://doi.org/10.1517/14740330802521771

Zobrazit plný text záznamu

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer

Autor: Jean-Louis Pujol, Jerzy Kozielski, Lukas C. Amler, Nigel Baker, Petr Zatloukal, Avi Ashkenazi, Yang Pan, Yong Jiang Hei, Fiona H Blackhall, Istvan Albert, Jean-Charles Soria, Barna Szima, D. Smethurst, Erzsébet Juhász, Howard M. Stern, Zsuzsanna Mark

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(33)

Purpose To evaluate the efficacy and safety of dulanermin combined with paclitaxel and carboplatin (PC) and bevacizumab (PCB) as first-line treatment for advanced or recurrent non–small-cell lung cancer (NSCLC). Patients and Methods Patients with s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c867223b8bb2a811bbe405ab28df8537
https://pubmed.ncbi.nlm.nih.gov/22010015

Zobrazit plný text záznamu

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

Autor: Erzsébet Juhász, Thaddeus Beck, Jean-Marc Limacher, Helen J. Ross, Anton Melnyk, Zsuzsanna Mark, Rosa Alvarez, Joseph Potz, Arnaud Scherpereel, Lecia V. Sequist, Jean-Philippe Oster, Elisabeth Quoix, Nandagopal Vrindavanam, John Nemunaitis, Piotr Jaskiewicz, Saiama N. Waqar

Publikováno v: Journal for Immunotherapy of Cancer

Meeting abstracts TG4010 immunotherapy product is a poxvirus (MVA) coding for MUC1 tumor-associated antigen and interleukin-2. A previous study showed that a normal baseline level of Triple Positive Activated Lymphocytes (TrPAL, CD16+CD56+CD69+) migh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b44054eb9b4d7a1e3a215ce3a1786bc
http://europepmc.org/articles/PMC4288318

Zobrazit plný text záznamu